This reflects what we see from the recruiter’s side of the table, which is a useful vantage point when you are planning your own next move. Moving from pharmaceutical leadership into medical devices is a genuinely achievable transition, but it is not the lateral step it often appears to be, because the development rhythm, regulatory framework, and commercial model all differ. Pharma executives who make this move successfully are the ones who understand what actually transfers and are honest about what does not.
Key Takeaways
- Pharma and device development rhythms differ substantially.
- The regulatory frameworks are distinct, not variations of one another.
- Device commercial models depend heavily on adoption and capital cycles.
- Regulated-industry judgment and clinical fluency transfer well.
- Be explicit about what you will need to learn.
What Transfers Well
Several things from pharma leadership carry over strongly. Operating inside a heavily regulated environment, with the discipline, documentation, and risk awareness that requires, transfers directly. Clinical development experience translates meaningfully, since device companies increasingly need serious clinical evidence. Reimbursement and market access sophistication is often more developed in pharma and is highly valued in devices. Working with health systems, payors, and physicians is common ground. These are real assets, and device companies value them, particularly as the sectors converge around evidence and access.
What Genuinely Differs
The differences are also real. Device development is typically faster, more iterative, and more engineering-driven, with product changes and improvements happening on cycles that pharma does not have. The regulatory framework is structurally different, with design controls, device classification, and pathways that do not map onto drug development. Manufacturing and quality systems operate differently. Commercially, devices often involve capital equipment cycles, surgeon or clinician adoption, training, and utilization dynamics rather than prescription-driven demand. Underestimating these differences is the main way this transition goes wrong.
Position the Transition Honestly
In interviews, the strongest position is candid: name clearly what transfers and what you will need to learn, and show that you understand the differences specifically rather than generically. A pharma executive who says they will bring rigorous clinical and market access capability while acknowledging they need to build device regulatory and manufacturing understanding reads as credible and self-aware. One who presents devices as essentially similar to pharma reads as someone who has not done the work, which is disqualifying with device interviewers who know the difference intimately.
Target the Right Entry Points
Some device contexts are far more accessible from pharma than others. Combination products, drug-delivery devices, diagnostics, and companies where clinical evidence and reimbursement drive the business play to pharma strengths. Roles in clinical, medical affairs, market access, and commercial are more transferable than device engineering, manufacturing, or device-specific regulatory leadership. Targeting the intersections where your background is genuinely advantageous, rather than competing head-on for roles where device-native candidates dominate, makes the transition substantially more achievable.
What This Looks Like in Practice
A pharma executive moving into devices identifies the intersections where their background is genuinely advantageous, combination products, diagnostics, clinical, medical affairs, market access, names candidly what transfers and what they must learn, and demonstrates specific rather than generic understanding of device development, regulation, and commercialization.
The Mistake Candidates Keep Making
The most common mistake is treating the move as a lateral step between similar regulated healthcare industries, and presenting it that way in interviews. Device interviewers know the frameworks and rhythms differ substantially, so a candidate who glosses over the differences signals that they have not seriously examined the transition. The candidate mistakes surface similarity for genuine transferability and loses credibility in the first substantive conversation.
What Transfers and What Does Not
| Area | Transferability |
|---|---|
| Regulated-environment judgment | Transfers directly |
| Clinical development | Transfers well |
| Reimbursement and market access | Often a strength from pharma |
| Device regulatory framework | Must be learned |
| Manufacturing and design controls | Must be learned |
| Adoption and capital sales dynamics | Must be learned |
The Bottom Line
Moving from pharma to device leadership works when you target the intersections where your clinical, regulatory-environment, and market access strengths genuinely apply, and when you are candid about the device-specific regulatory, manufacturing, and commercial dynamics you will need to learn rather than treating the sectors as interchangeable. None of this is quick, but it compounds, and the candidates who start early are the ones with options later.
Related Reading
For more, see Career Paths from Engineer to Medical Device Executive, What Recruiters Look for in MedTech Candidates, Preparing for Interviews at Top MedTech Companies.
Frequently Asked Questions
- Q: What transfers from pharma to devices?
- A: Regulated-environment judgment, clinical development experience, reimbursement and market access sophistication, and experience with health systems, payors, and physicians.
- Q: What is most different?
- A: Device development is faster and more iterative and engineering-driven, the regulatory framework is structurally distinct, and commercialization often turns on adoption, training, and capital cycles.
- Q: How should I position the transition?
- A: Candidly, naming specifically what transfers and what you must learn, since device interviewers know the differences intimately and glossing over them costs credibility.
- Q: Which device roles are most accessible from pharma?
- A: Clinical, medical affairs, market access, and commercial roles, particularly in combination products, drug-delivery devices, and diagnostics where evidence and reimbursement drive the business.
- Q: What is the main way this transition fails?
- A: Underestimating the differences and presenting devices as essentially similar to pharma, which signals to interviewers that the candidate has not examined the move seriously.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
